Welcome to our dedicated page for SANGAMO THERAPEUTICS SEC filings (Ticker: SGMO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Sangamo Therapeutics filings document regulatory, clinical, financial and corporate-status disclosures for a genomic medicine company developing gene therapy and genome-engineering technologies. Recent 8-K reports cover operating and financial results, clinical data from the STAAR study of isaralgagene civaparvovec, or ST-920, regulatory-pathway disclosures for Fabry disease, and material-event updates tied to the company's neurology pipeline.
The filing record also includes Nasdaq listing-compliance and delisting notices, SGMO common-stock registration information, finance leadership and officer-transition disclosures, and capital-structure information. These documents formalize the company's reported results, governance changes, securities status and clinical-regulatory events under SEC reporting rules.
Sangamo Therapeutics reported a first quarter 2026 net loss of $31.0 million, or $0.08 per share, compared with a net loss of $30.6 million, or $0.14 per share, a year earlier. Revenue fell to $1.4 million from $6.4 million, mainly due to lower collaboration and license revenue.
GAAP operating expenses declined to $33.4 million, with non-GAAP operating expenses at $31.7 million, as the company reduced personnel and facilities costs while increasing spending on BLA readiness for its Fabry disease program. Cash and cash equivalents were $27.6 million as of March 31, 2026, which Sangamo estimates will fund operations into the third quarter of 2026.
The company advanced a rolling BLA for Fabry candidate ST-920 under an FDA Accelerated Approval pathway and continued early-stage neurology programs in chronic neuropathic pain and prion disease. Sangamo’s stock was suspended from Nasdaq for not meeting the minimum bid price and began trading on the OTCQB Venture Market on May 5, 2026, while the company appeals Nasdaq’s delisting determination.
Sangamo Therapeutics filed an amended annual report to add detailed Part III information on directors, executive compensation, ownership and governance without changing previously reported financial results. The amendment also refreshes officer certifications.
The filing outlines a 2025 executive pay program where CEO Alexander Macrae’s total compensation was about $2.6 million, including equity awards and a cash bonus earned under a plan that reached 40% of corporate goals. All 2025 bonuses and approved 2025 salary increases for named executives remain deferred until the company raises additional funding, and Macrae voluntarily waived his 2025 bonus.
Board and committee retainers, director equity grants, and extensive outstanding stock option and RSU positions are described, along with major 2025 and early 2026 equity financings that raised roughly $21.1 million and $23.1 million. As of April 20, 2026, Sangamo had 414,275,509 shares outstanding, with Armistice Capital and Yorkville each holding more than 10% of the common stock, subject to warrant-related beneficial ownership limits.
Sangamo Therapeutics has been notified by Nasdaq that its common stock will be delisted for continued failure to meet the $1.00 per share minimum bid price requirement. Nasdaq plans to suspend trading on the Nasdaq Capital Market at the open on May 5, 2026.
The company plans to request a hearing before a Nasdaq Hearings Panel, which would stay the delisting determination but not the trading suspension. Sangamo has obtained approval for its shares to be quoted on the OTCQB Venture Market and expects OTCQB trading to begin on May 5, 2026 under the symbol SGMO.
Sangamo Therapeutics executive Gregory D. Davis, Head of Research & Technology, sold common stock in an open-market transaction. On April 22, 2026, he sold 69,827 shares of Sangamo Therapeutics common stock at a weighted-average price of $0.2534 per share, with individual trades ranging from $0.2533 to $0.2568. After this sale, Davis directly holds 115,284 shares of the company’s common stock.
Sangamo Therapeutics SVP-Chief Development Officer Nathalie Dubois-Stringfellow reported an open-market sale of Common Stock. She sold 345,942 shares on April 21, 2026 at a weighted-average price of $0.2578 per share in multiple trades ranging from $0.2533 to $0.2634.
Following this transaction, she directly holds 332,769 shares of Sangamo Therapeutics Common Stock. The filing does not report any derivative security exercises, indicating this was a straightforward share sale rather than an option-related transaction.
Filer submitted a Form 144 notifying a proposed sale of Common Stock. The notice lists securities held through E*TRADE from Morgan Stanley and documents multiple past acquisitions via ESPP purchases and vested restricted stock units. Examples include a 438,758 shares lot vested on 01/22/2026 and other grants on 02/25/2025 and 02/24/2026.
Sangamo Therapeutics senior vice president and chief development officer Nathalie Dubois-Stringfellow received a grant of stock options covering 800,000 shares of common stock. The options have an exercise price of $0.2601 per share and expire on March 31, 2036.
One quarter of the options will vest on the first anniversary of the grant date, with the remaining options vesting in 24 equal monthly installments, contingent on her continued service under the company’s 2018 equity incentive plan.
Sangamo Therapeutics Principal Accounting Officer Nikunj Jain received a grant of stock options as equity compensation. The award covers 225,000 options to buy common stock at an exercise price of $0.2601 per share, expiring on March 31, 2036.
One quarter of the options vest on the first anniversary of the grant date, and the remaining options vest in 24 equal monthly installments, subject to Mr. Jain’s continuous service and the terms of the company’s 2018 equity incentive plan. No open‑market share purchases or sales were reported in this filing.
Sangamo Therapeutics reported that Head of Research & Technology Gregory D. Davis received a new stock option grant. The award covers 225,000 stock options for common shares at an exercise price of $0.2601 per share, expiring on March 31, 2036.
One-quarter of the options will vest on the first anniversary of the grant, with the remaining options vesting in 24 equal monthly installments, contingent on his continued service under the company’s 2018 equity incentive plan. After this grant, he holds 225,000 derivative securities directly.